Clinical trials of the coronavirus vaccine, developed jointly with the German company BioNTech and the US corporation Pfizer Inc., will be held in Germany, Report says, citing Izvestia.
According to the information, if the tests are successful, the companies plan to place the vaccine on the market in October.
The Paul Ehrlich Institute has already approved the second and third rounds of experimentation. The Germany tests will be part of an international study launched in July; thus, about 30,000 volunteers are expected to participate in it. Currently, more than 25,000 aides participate in clinical trials conducted in 120 research centers around the world.
Ugur Shahin, one of the founders of BioNTech, said that extensive, controlled three-stage tests are important to confirm the safety and effectiveness of the vaccine.
If the drug enters the market, it will release up to 100 million doses by the end of this year. This figure may increase to more than 1.3 billion doses in 2021.